Neurocrine Biosciences Inc

1NBIX

Company Profile

  • Business description

    Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

  • Contact

    6027 Edgewood Bend Court
    San DiegoCA92130
    USA

    T: +1 858 617-7600

    E: [email protected]

    https://www.neurocrine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    2,500

Stocks News & Analysis

stocks

ASX utility share downgraded as electricity prices fall

Falling electricity prices weigh on earnings outlook for utility provider.
stocks

Chart of the Week: AI market leader is now surprisingly cheap

This AI beneficiary may still be one of the market’s most compelling bargains.
stocks

Weekly earnings wrap: Rio Tinto leads the way

A closer look at the key earnings results from the first week of August reporting.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,452.0042.100.45%
CAC 408,728.6659.370.68%
DAX 4026,190.6564.350.25%
Dow JONES (US)54,349.12263.240.49%
FTSE 10010,933.7145.410.42%
HKSE25,530.28385.54-1.49%
NASDAQ26,363.44221.55-0.83%
Nikkei 22565,683.26617.18-0.93%
NZX 50 Index13,958.0639.12-0.28%
S&P 5007,723.5512.97-0.17%
S&P/ASX 2009,271.6041.800.45%
SSE Composite Index3,900.3521.920.57%

Market Movers